WuXi Biologics Schedules Key Financial Review
Wuxi Bio (02269.HK) held a board of directors meeting on August 21 to consider and approve the interim performance.
Wuxi Bio (02269.HK) announced that the board of directors will convene a meeting in Hong Kong on August 21, 2024 (Wednesday) to consider and approve the interim performance of the group for the six months ending June 30, 2024 (including).
WUXI BIO: DATE OF BOARD MEETING
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy
Wuxi Biologics Stock Looks Undervalued -- Market Talk
Wuxi Biologics Target Price Cut to HK$23.25 From HK$53.65 by Nomura >2269.HK
Contract research organizations are generally increasing. Pharmaron (03759) rose 6.66%, and Orient Securities is expected to see marginal improvement in the sector.
Jingu Financial News| The concept of contract research organizations is rising across the board. As of the time of publication, Pharmaron (03759) rose 6.66%, Viva Biotech (01873) rose 5.05%, Tigermed (03347) rose 2.84%, and Wuxi Bio (02269) rose 2.77%. On the news side, Orient Securities stated that according to the latest data on the key indicators of the CRO industry's prosperity index, the global fund has basically stabilized, while the domestic investment and financing side is still tight; however, the enthusiasm for research and development has not diminished, and the IND and new clinical trials are still at a high level. The bank believes that the CXO sector, after experiencing double killings in performance and valuation, is expected to welcome a
Unusual event report | CRO concept stocks rose collectively, with the top companies signing new orders with double-digit growth in amount, and the sector is expected to see marginal improvement.
CRO concept stocks collectively rose. As of press time, Pharmaron (03759) rose 7.23% to HKD 9.34, Viva Biotech (01873) rose 3.03% to HKD 0.51, and Tigermed (03347) rose 2.84% to HKD 30.75.
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Hong Kong stock market anomaly | CRO concept stocks collectively rose in the afternoon. The Fed's interest rate hiking cycle is nearing its end, and overseas CXO demand is expected to improve first.
Afternoon rally in CRO concept stocks, as of press time, Tigermed (03347) rose 9.85% to HKD 29.55; Frontage (01521) rose 6.58% to HKD 0.81; Pharmaron (03759) rose 4.72% to HKD 8.65; Asymchem Laboratories (06821) rose 2.47% to HKD 47.65; Wuxi Bio (02269) rose 1.97% to HKD 11.4.
Express News | BlackRock's Long Position in WuXi Biologics Increases to 5.23% on June 28 From 4.68% - HKEX Filing
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target Is HK$14
Wuxi Bio (02269.HK) received shareholding of 1.445 million shares from Director Li Ge.
According to the latest equity disclosure information from the Stock Exchange, on June 24, 2024, Wuxi Bio(02269.HK) non-executive director and chairman Li Ge acquired 1.445 million shares at an average price of HKD 11.5735 per share, involving approximately HKD 16.7237 million. After the shareholding, Li Ge's latest shareholding is 592,902,633 shares, and the shareholding ratio has increased from 14.24% to 14.28%.
Wuxi Bio (02269.HK) Chairman Li Ge increased shareholding by 1 million shares.
According to the latest equity disclosure of the HKEX, on June 21, 2024, Wuxi Bio(02269.HK) received Li Ge, the non-executive director and chairman, for shareholding of 1 million shares at an average price of HKD 11.6367 per share, with a total amount of approximately HKD 11.637 million. After the shareholding, Li Ge's latest shareholding number increased from 14.22% to 14.24%.
Wuxi Bio (02269) saw a rise of more than 5% in the afternoon stock market, the company previously responded to the reason for the suspension of construction of the Worcester base in the United States.
Wuxi Bio (02269) rose more than 5% in the afternoon. As of the time of publication, it rose 3.28%, with a price of HK$11.98 and a turnover of HK$393 million.
Wuxi Bio (02269.HK) received a shareholding of 200,000 shares from Chairman Li Ge.
On June 20, 2024, according to the latest equity disclosure information of the Hong Kong Stock Exchange, Wuxi Bio (02269.HK), in which Li Ge is a non-executive director and chairman, increased its shareholding by 200,000 shares on the exchange with an average price of HKD 11.9171 per share, involving a total of approximately HKD 2.3834 million. After the shareholding increase, Li Ge's latest holding amount is 590,457,633 shares, and the shareholding ratio has increased from 14.21% to 14.22%.
No Data